Menatetrenone (vitamin K2) acts directly on circulating human osteoclast precursors

Calcified Tissue International

Volumn 73, Issue 1, 2003, Pages 78-85

  Taira, H ^a   Fujikawa, Y ^a   Kudo, O ^a   Itonaga, I ^a   Torisu, T ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Bone resorption; Geranylgeraniol; Menatetrenone; Osteoclast differentiation; Osteoclasts

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; FARNOQUINONE; OSTEOCLAST DIFFERENTIATION FACTOR; ACID PHOSPHATASE; ANTIFIBRINOLYTIC AGENT; DITERPENE; GERANYLGERANIOL; ISOENZYME; PHYTOL; PHYTOMENADIONE; TARTRATE-RESISTANT ACID PHOSPHATASE;

ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; VITAMIN METABOLISM; CELL COUNT; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GIANT CELL; METABOLISM; MONONUCLEAR CELL;

ACID PHOSPHATASE; ANTIFIBRINOLYTIC AGENTS; BONE RESORPTION; CELL COUNT; CELL DIFFERENTIATION; CELLS, CULTURED; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GIANT CELLS; HUMANS; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; OSTEOCLASTS; PHYTOL; STEM CELLS; VITAMIN K 1; VITAMIN K 2;

EID: 0042889302     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-002-2061-y     Document Type: Article

References (20)

1. Fujikawa Y, Quinn J, Sabokbar A, McGee J, Athanasou N (1996) The human osteoclast precursor circulates in the monocytes fraction. Endocrinology 137:4058-4060
2. Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu YX, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli YX, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi J, Guo J, Deraney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki N, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda A, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiating factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
4. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga N, Toyama Y, Yabe Y, Higashio K, Suda T (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246:199-204
5. Quinn JN, Elliott J, Gilliespie MT, Marti TJ (1998) A combination of osteoclast differentiating factor and macropharge-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424-4427
6. Olsen RE, Suttie JW (1977) Vitamin K and gamma-carboxyglutamate biosynthesis. Vitam Horm 35:59-108
7. Akiyama Y, Hara K, Ohkawa I, Tajima T (1993) Effect of menatetrenone on bone loss induced by ovariectomy in rats. Jpn J Pharmacol 62:145-153
8. Hara K, Akiyama Y, Ohkawa I, Tajima T (1993a) The effect of menatetrenone on prednisolone-induced bone loss in rats. Bone 14:813-818
9. Hara K, Akiyama Y, Tajima T, Shiraki M (1993b) Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J Bone Miner Res 8:535-542
10. 2 (menatetrenone) on osteoclast-like cell formation in mouse bone marrow culture. Eur J Pharmacol 263:181-185
11. 2 (menatetrenone) on bone resorption may be related to its side chain. Bone 16:179-184
12. Stenflo J, Fernlund P, Egan W, Roepstorf (1974) Vitamin K-dependent modification of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 71:2730-2733
13. Caraballo PJ, Heit JA, Atkinson EJ, Silverstein MD, O'Fallon WM, Castro MR, Melton 3rd LJ (1999) Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 159:1750-1756
14. Feskanich D, Weber P, Willett WC, Rockett H, Booth GA, Colditz GA (1999) Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 69:74-79
15. Knapen MH, Hamulyak K, Vermeer C (1989) The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 111:1001-1005
16. Takeuchi Y, Suzawa M, Fukumoto S, Fujita T (2000) Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. Bone 27:769-776
17. Ishii M, Shimomura M, Hasegawa J, Yamato C, Asano Y, Yamano Y, Okano K, Yamazaki K, Momono M, Kanamaru M, Nakasima M (1995) Multiple dose pharmacokinetic study of soft gelatin capsule of menatetrenone (Ea-0167) in eldely and young volunteers. Jpn Pharmacol Ther 23:2637-2642
18. 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone density in osteoporosis. J Bone Miner Res 15:515-521
19. Fisher JE, Rogers MJ, Harasy JM, Luckman SP, Hughs PJ, Masarachia PJ, Wesolowski G, Russell RGG, Rodan AA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138
20. Fujikawa Y, Sabokbar A, Neale SD, Itonaga I, Torisu T, Athanasou NA (2001) The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 28:261-267